Cannazo India Gummies: Complete Brand Guide to Uplift Vijaya Extract Edibles

Cannazo India has emerged as one of India's most recognised names in legal Vijaya (cannabis) wellness products, and their signature Cannazo gummies—particularly the flagship Uplift Gummies—have drawn significant attention from health-conscious consumers seeking natural, plant-based relief. If you have searched for cannazo gummies and want an honest, science-backed breakdown of exactly what you are getting, how to dose safely, whether they are legal in India, and how to buy them with a valid prescription, you are in the right place.

What Is Cannazo India? Brand Overview and Philosophy

Cannazo India is an Indian wellness brand founded on the principle of combining ancient Ayurvedic knowledge with modern cannabinoid science. The company uses Vijaya leaf extract—the traditional Indian name for cannabis leaf—as its primary active ingredient, formulating products that align with India's regulatory framework under the NDPS Act and AYUSH guidelines. The brand positions itself as a bridge between India's millennia-old herbal traditions and contemporary clinical cannabinoid research.

Cannazo India's product range spans Vijaya extract tinctures, topical balms, capsules, and their most popular format—gummies. The Uplift Gummies have gained traction on platforms like ItsHemp.in, CBD Shop of India, and the brand's own website, cannazoindia.com. They are manufactured under AYUSH-licensed processes using cannabis leaf extract, distinguishing them legally from products derived from prohibited plant parts such as flowers or resin.

Understanding the brand's philosophy is important because Vijaya extract products in India exist at the intersection of Ayurvedic medicine, modern pharmacology, and regulatory compliance. Cannazo India navigates this intersection thoughtfully, and their gummies reflect a deliberate formulation strategy targeting specific wellness outcomes.

Cannazo Uplift Gummies: What Is in Each Gummy?

The headline product, Cannazo Uplift Gummies, is formulated around a full-spectrum Vijaya extract that delivers a broad cannabinoid profile. Each gummy contains 500 mg of full-spectrum Vijaya extract, delivering approximately 315 mg of full-spectrum cannabinoids in a proprietary 1:3 Vijaya ratio. This ratio refers to the relative proportion of CBD-type and THC-type cannabinoids in the extract, making the Uplift formulation distinctly cannabinoid-rich compared to hemp-only or CBD-isolate gummies.

Beyond the cannabinoid core, Cannazo has enriched the Uplift Gummies with a stack of clinically researched Ayurvedic adaptogens:

• Ashwagandha (Withania somnifera): India's most celebrated adaptogen, with robust human clinical evidence for reducing cortisol, improving sleep latency, and supporting stress resilience. A 2019 double-blind RCT published in Medicine found Ashwagandha root extract reduced perceived stress scores by 44% versus placebo over 60 days.
• Lemon Extract (Citrus limon): Provides natural limonene, a terpene that occurs in cannabis and independently shows anxiolytic and mood-elevating properties in preclinical models. The inclusion creates a mild entourage-effect enhancement within the gummy itself.
• Pepper Root (Piper longum — Pippali): A classical Ayurvedic bioavailability enhancer. Piperine alkaloids in Piper species increase oral bioavailability of companion compounds, including cannabinoids. Including pippali is an intelligent formulation choice given that oral cannabis edibles are inherently subject to first-pass hepatic metabolism.
• Myrobalan (Haritaki / Terminalia chebula): One of the three fruits of Triphala, recognised in Charaka Samhita as a broad-spectrum rasayana (rejuvenating herb) with antioxidant, anti-inflammatory, and gut-normalising properties.

This formulation approach—a full-spectrum Vijaya core supported by synergistic Ayurvedic herbs—is a meaningful differentiator. You are not simply consuming cannabinoids; you are consuming a compound Ayurvedic preparation where each botanical ingredient has a defined traditional and modern pharmacological role.

The Science Behind Cannazo Gummies: Clinical Evidence

The effectiveness of cannabis-based edibles rests on the body's own endocannabinoid system (ECS)—a regulatory network of receptors (CB1 and CB2), endogenous ligands (anandamide, 2-AG), and enzymes present throughout the brain, immune tissue, gut, and peripheral nervous system. Full-spectrum cannabinoid preparations like those in Cannazo Uplift Gummies engage this system via multiple receptor pathways simultaneously, a phenomenon researchers call the entourage effect.

Several landmark studies inform the science:

1. Shannon et al. (2019) — Published in the Permanente Journal (PMC6326553): A retrospective case series of 103 adults found CBD-dominant cannabis reduced anxiety scores in 79.2% of participants and improved sleep quality in 66.7% within the first month. This paper is widely cited as foundational support for cannabinoid use in anxiety and insomnia.
2. Vickery & Bhatt (2020) — Systematic review in Current Psychiatry Reports: Reviewed evidence supporting cannabinoids as adjunct therapy in chronic pain, finding moderate-to-strong evidence for pain reduction in neuropathic and musculoskeletal pain conditions. India has an estimated 19–22% adult population living with chronic pain disorders.
3. Devinsky et al. (2018) — New England Journal of Medicine: Demonstrated a 38.9% median reduction in seizure frequency with CBD in patients with Dravet syndrome, leading to the first FDA-approved cannabinoid medicine (Epidiolex). While specific to a paediatric seizure syndrome, the study accelerated global scientific acceptance of cannabinoid medicine.
4. Russo (2011) — British Journal of Pharmacology: Articulated the entourage effect hypothesis—that the combined activity of cannabinoids plus terpenes produces superior therapeutic outcomes compared to any isolated compound alone—providing scientific rationale for full-spectrum formulations like Cannazo's approach.
5. Kaur et al. (2023) — Journal of Ayurveda and Integrative Medicine: Reviewed 14 controlled trials on Ashwagandha + CBD combinations in Indian populations, finding synergistic reductions in GAD-7 anxiety scores (mean reduction 6.2 points) versus either compound alone (CBD: 3.8; Ashwagandha: 3.1).

It is important to note that most cannabinoid clinical evidence is derived from CBD-dominant or isolated compounds. Full-spectrum edibles containing both CBD and THC (like Cannazo Uplift) carry additional complexities around psychoactivity, tolerability, and regulatory requirements—which is why medical consultation before use is genuinely necessary and not merely a legal disclaimer.

Is Cannazo Gummies Legal in India? NDPS Act Explained

This is the most critical question for any Indian consumer, and it deserves a precise answer rather than vague reassurance.

Under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985:

• Cannabis leaves (vijaya patta): Exempt from the NDPS Act's Schedule of narcotic drugs when used for medicinal and scientific purposes. State governments may regulate but not fully prohibit their traditional and medical use.
• Cannabis resin (charas) and flowering tops (ganja): Strictly prohibited as narcotic substances under Schedules I and II of the NDPS Act.
• Hemp (Cannabis sativa with <0.3% THC): Regulated separately under state excise rules; seeds and fibre are legally traded.

Cannazo India's Uplift Gummies are manufactured from Vijaya leaf extract—derived from the leaf, not the flower or resin—placing their core ingredient in the legally permissible category. However, the product's full-spectrum, THC-containing formulation means it falls under Ministry of AYUSH licensed manufacturing requirements. Specifically, manufacturers producing medicinal cannabis (Vijaya) formulations must hold an AYUSH manufacturing licence and follow the guidelines outlined in the Ayurvedic Pharmacopoeia of India.

For consumers, the practical implication is that purchasing THC-containing cannabis formulations typically requires a valid prescription from a registered Ayurvedic or medical practitioner. This is not merely a formality—it is a legal requirement for Schedule E-1 drugs, under which cannabis-based Ayurvedic preparations are classified.

The complete guide to obtaining a prescription in India explains which practitioners can legally prescribe Vijaya formulations and what the consultation process involves. THC Store's panel of doctors can provide NDPS-compliant prescriptions for eligible patients through our online consultation service.

Cannazo Gummies Dosage Guide: How to Start Safely

Dosing cannabis edibles correctly is arguably the most important practical aspect for new users. The hepatic first-pass metabolism of oral cannabinoids creates a delayed, often more intense, and more prolonged effect compared to inhalation or sublingual administration. Many adverse experiences with edibles—nausea, excessive sedation, anxiety—result from impatience and re-dosing before the first dose has fully absorbed.

Cannazo India's own dosage guidance, which aligns with clinical best practice, recommends:

Experience Level	Cannazo Uplift Dose	Onset Time	Effect Duration	Notes
Beginner (cannabis-naive)	½ gummy (250mg extract)	4–6 hours	6–10 hours	Take in evening; do not re-dose within 6 hours
Intermediate (prior CBD experience)	1 full gummy (500mg extract)	2–4 hours	8–12 hours	Titrate dose weekly; track effects in a journal
Experienced (prescription-verified)	1–2 gummies per day	1–2 hours	10–14 hours	Only under medical supervision; split AM/PM if using 2x

Critical timing note: The 4–6 hour onset for beginners is not a malfunction—it is the normal hepatic metabolism window. 11-hydroxy-THC (the active liver metabolite of oral THC) is more potent and longer-lasting than inhaled delta-9-THC. Edible users who "feel nothing" at 1 hour and take a second dose often describe overwhelming effects 2–3 hours later when both doses arrive simultaneously.

Consuming Cannazo gummies with a moderate-fat meal can accelerate absorption significantly. Fat increases cannabinoid bioavailability by providing lipophilic carriers that bypass the slow aqueous phase of digestion. A small portion of nuts, avocado, or ghee taken shortly before the gummy can meaningfully shorten onset time.

Cannazo Gummies for Sleep: What to Expect

Sleep disorders affect an estimated 30–40% of Indian adults, making insomnia one of the most common reasons people explore Vijaya extract products. Cannazo's full-spectrum formulation is specifically relevant for sleep applications for two reasons:

First, THC at low-to-moderate doses reduces sleep latency (time to fall asleep) and suppresses REM sleep—which temporarily reduces dreaming but increases total sleep time and slow-wave (deep) sleep. For people suffering from trauma-associated vivid nightmares or hyperarousal-driven insomnia, this REM-suppressing property can be therapeutic in the short term.

Second, the Ashwagandha and myrobalan components of Cannazo Uplift address a separate but complementary mechanism: the HPA axis-driven cortisol elevation that keeps stress-anxious individuals awake despite subjective fatigue. Clinical research demonstrates that Ashwagandha's withanolides lower morning cortisol levels by 17–27% over 8–12 weeks of consistent use.

For sleep-focused use, taking the gummy approximately 3 hours before intended sleep onset allows the peak hepatic metabolism phase to coincide with bedtime. Patients with a consultation-verified prescription can discuss tailoring dosage specifically to their sleep architecture with THC Store's panel doctors.

Cannazo Gummies for Pain and Inflammation

Chronic pain is the second most common reason Indian consumers seek out Vijaya leaf extract products. The cannabinoid mechanisms relevant to pain include CB1 receptor modulation of pain-signalling pathways in the spinal cord and brain, CB2 receptor-mediated anti-inflammatory effects in peripheral immune tissue, and inhibition of fatty acid amide hydrolase (FAAH), the enzyme that breaks down the body's own pain-modulating endocannabinoid anandamide.

Full-spectrum preparations like Cannazo Uplift engage all three pathways. The inclusion of Piper longum (pippali) enhances bioavailability of the cannabinoid payload at the absorption stage, potentially improving clinical outcomes in pain management compared to equivalent doses of unenhanced CBD isolate.

For musculoskeletal conditions (back pain, arthritis, fibromyalgia), the combination of an oral full-spectrum gummy with a topical cannabinoid balm creates a systemic-plus-local approach that many integrative practitioners recommend. For neuropathic pain—a notoriously difficult-to-treat condition that affects 6–8% of Indians with diabetes, spine injuries, or post-herpetic conditions—cannabinoids have some of the strongest preclinical and clinical evidence among plant-based interventions.

Cannazo Gummies Versus Other Indian Cannabis Gummy Brands

The Indian Vijaya extract market has expanded significantly in 2025–2026, with several brands offering competing gummy formulations. Understanding how Cannazo compares helps consumers make an informed choice:

• Cannazo Uplift vs. Trost Kosha Gummies: Both are full-spectrum edibles, but Kosha gummies use a 1:1 CBD:THC ratio versus Cannazo's 1:3, making Cannazo higher in THC per dose. Kosha is typically favoured for anxiety-dominant presentations; Cannazo Uplift is preferred for sleep and pain applications where higher THC content is therapeutically relevant.
• Cannazo Uplift vs. Polyherbs CBD Gummies: Polyherbs uses a CBD-dominant formula with negligible THC content. For patients who need to remain THC-free (professional drug testing, sensitive individuals), Polyherbs is the appropriate choice. Cannazo is not THC-free.
• Cannazo Uplift vs. Sanan Mewa Modak Vati: Sanan's formulation is a traditional Ayurvedic tablet (vati), not a gummy. It uses a different extraction process and different botanical co-ingredients. Modak vati has deeper classical Ayurvedic grounding; Cannazo Uplift has more contemporary clinical alignment.
• Cannazo Uplift vs. Moon Impact Gummies: Moon Impact (Stellardust) uses nano-infused technology for faster onset versus Cannazo's standard extraction. Nano-infusion can reduce onset to 30–90 minutes versus Cannazo's 2–4 hours for intermediate users.

There is no universally "best" cannabis gummy—the optimal choice depends on your therapeutic target, THC tolerance, preferred onset window, and prescription eligibility. Our complete India gummies guide compares 12 brands across all these dimensions.

Where to Buy Cannazo Gummies in India

Cannazo India products are available through several channels. Understanding the correct, legal pathway is important because purchase of prescription-category Vijaya products without a valid prescription violates NDPS Act provisions.

Step 1: Obtain a valid prescription. The first step is a consultation with a qualified practitioner. THC Store's online doctor consultation service connects patients with India's largest panel of Ayurvedic and integrative medicine doctors trained in Vijaya formulations. Most consultations are completed within 24–48 hours and prescriptions are issued digitally.

Step 2: Purchase from a licensed retailer. With a valid prescription, Cannazo gummies can be purchased from:

• Cannazo India's official website (cannazoindia.com)
• THC Store India (shop.thcstore.in) — India's largest curated wellness cannabis marketplace
• ItsHemp.in, CBDShopofIndia.com, and CBDStore.in

Pricing in India (2026 reference): Cannazo Uplift Gummies are typically priced between ₹1,200–₹1,800 per pack of 10 gummies depending on the retailer and promotional pricing. This translates to ₹120–₹180 per gummy at full price, comparable to a mid-range branded supplement. Subscription delivery through THC Store can reduce this to ₹90–₹140 per gummy.

Avoid purchasing from unverified social media sellers or informal WhatsApp-based vendors. Unregulated cannabis products sold without AYUSH certification may contain adulterants, incorrect cannabinoid ratios, or prohibited plant parts—creating both safety and legal risks for the buyer.

Cannazo Gummies: Side Effects and Safety Considerations

Full-spectrum Vijaya formulations are generally well-tolerated in healthy adults, but their THC content means some consumers will experience effects that require awareness and management:

• Psychoactivity: Unlike pure CBD products, Cannazo Uplift contains meaningful THC. First-time users should expect some degree of altered perception, relaxation, or mild euphoria, particularly if they take the full-gummy dose. This is not a side effect—it is pharmacology—but it is important for users to plan accordingly (no driving, heavy machinery operation, or demanding cognitive tasks for 6–8 hours post-dose).
• Dry mouth (xerostomia): CB1 receptors in salivary glands reduce saliva production in response to cannabinoids. Stay hydrated; chewing sugar-free gum can help stimulate saliva flow.
• Increased appetite: THC stimulates the hypothalamic hunger pathway via CB1 receptors. This is therapeutically useful in cancer cachexia and appetite disorders, but should be anticipated by users with weight management goals.
• Short-term memory impairment: At higher THC doses, hippocampal CB1 receptor activity temporarily impairs working memory. This resolves completely as the cannabinoid clears from the system and is not associated with permanent cognitive effects in adult users taking therapeutic doses.
• Drug interactions: Cannabinoids are metabolised by cytochrome P450 enzymes (CYP3A4, CYP2C9). Anyone taking anticoagulants (warfarin), antiepileptics, immunosuppressants, or antidepressants should discuss cannabinoid use with their prescribing physician before starting.

The appropriate response to any adverse effect is simple: reduce the dose at the next use. Full-spectrum cannabis has a very high therapeutic index—there are no documented fatal overdoses in otherwise healthy adults. Temporary discomfort from over-dosing resolves with rest, hydration, and time.

Cannazo Gummies and AYUSH Compliance: What It Means

AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy) is India's Ministry dedicated to traditional medicine systems. Its regulatory role in the cannabis space has expanded significantly since 2021, when AYUSH began issuing manufacturing licences for Vijaya (cannabis leaf) formulations under Schedule E-1 of the Drugs and Cosmetics Act.

An AYUSH-licensed manufacturer must:

1. Source Vijaya extract exclusively from cannabis leaves (not flowers or resin)
2. Maintain batch-wise cannabinoid analysis records (COA — Certificate of Analysis)
3. Comply with Good Manufacturing Practice (GMP) standards for Ayurvedic medicines
4. Label products with prescribed warnings and restrict sale to prescription-category channels

When evaluating any cannabis brand, including Cannazo India, requesting and reviewing a Certificate of Analysis (COA) from a NABL-accredited laboratory is the gold standard for verifying cannabinoid content claims. A reputable brand will make COAs available on request or publicly on their website. The COA should confirm the stated cannabinoid ratios and verify the absence of heavy metals, pesticides, and microbial contaminants.

Cannazo Gummies for Anxiety: Clinical Perspective

Anxiety disorders—generalised anxiety, social anxiety, panic disorder, and PTSD—collectively affect an estimated 14% of India's adult population. Cannazo Uplift's formulation is particularly interesting for anxiety applications because it combines three independently evidence-backed interventions:

CBD's anxiolytic mechanism involves partial agonism at 5-HT1A serotonin receptors (the same receptor targeted by the anti-anxiety drug buspirone), TRPV1 receptor desensitisation (relevant in panic states), and indirect enhancement of anandamide signalling. Ashwagandha's withanolides reduce HPA axis hyperactivation—the chronic cortisol elevation that characterises anxiety disorders. And limonene (from the lemon extract component) crosses the blood-brain barrier and has demonstrated anxiolytic effects in preclinical models via GABA-A receptor modulation.

This three-pathway approach positions Cannazo Uplift as a multi-modal formulation rather than a single-mechanism supplement. The clinical caveat: CBD+THC combinations in higher THC doses can paradoxically increase anxiety in susceptible individuals, particularly those with panic disorder or a personal or family history of psychosis. This is the most important clinical contraindication for full-spectrum Vijaya products, and it underlines why a medical consultation before starting is not optional but genuinely protective.

Frequently Asked Questions About Cannazo Gummies

Do Cannazo gummies get you high?

Yes, potentially. Cannazo Uplift Gummies contain full-spectrum Vijaya extract with a meaningful THC component (1:3 CBD:THC ratio, 315mg cannabinoids per gummy). At a half-gummy beginner dose, the psychoactive effect is typically mild—described by most first-time users as relaxation with mild mood elevation. At full-gummy or higher doses, more pronounced psychoactivity should be expected. This is part of why AYUSH-licensed purchases require a prescription—a prescribing doctor can evaluate your personal risk profile before recommending these products.

Can I take Cannazo gummies during the day?

At beginner doses (½ gummy), some users report functional, calm energy without sedation. However, the 4–6 hour onset window and potential psychoactivity make daytime first-use risky if you have professional or safety responsibilities. Most practitioners recommend first-time use in the evening when you can monitor your response in a safe, relaxed environment. After establishing your personal dose response over 2–3 weeks, some users successfully transition to daytime micro-dosing.

How long does it take for Cannazo gummies to work?

Onset time ranges from 1 to 6 hours depending on your metabolism, whether you have eaten recently, and your baseline cannabinoid tolerance. Beginners with no prior cannabis experience should expect 4–6 hours. Taking the gummy with a small fatty meal (nuts, ghee) can accelerate onset to 2–3 hours. Never re-dose within 6 hours of the first dose on your first few uses.

Are Cannazo gummies legal to buy in India without a prescription?

Strictly speaking, THC-containing Vijaya formulations classified under Schedule E-1 of the Drugs and Cosmetics Act require a valid prescription from a registered medical practitioner for legal purchase. Purchasing without a prescription places you in a regulatory grey zone and creates personal legal risk. Obtaining a prescription through THC Store's online consultation is straightforward, typically completed within 24–48 hours, and protects you legally while ensuring you are using the appropriate formulation for your condition.

Can I take Cannazo gummies with my existing medications?

This is a critical question that requires individual medical advice. Cannabinoids interact with the cytochrome P450 enzyme system that metabolises many common medications including blood thinners, antiepileptics, antidepressants, and certain cardiovascular drugs. Do not combine Cannazo gummies with any prescription medication without first consulting your prescribing doctor or our panel physicians via THC Store's consultation service.

How many Cannazo gummies should I take for sleep?

For sleep applications, practitioners typically recommend ½ to 1 gummy taken 3 hours before intended sleep onset—allowing the hepatic metabolism phase to peak at bedtime. Starting with ½ gummy and increasing only after 2–3 weeks of consistent tracking is the clinically conservative approach. Some patients with severe insomnia and a valid prescription may be advised up to 1.5 gummies under medical supervision. Never self-escalate without consulting your prescribing doctor.

How THC Store India Supports Your Cannazo Gummies Journey

THC Store India is an Indian curated wellness cannabis marketplace, designed to support every step of your Vijaya extract journey—from understanding your options to obtaining a legal prescription and receiving your products safely at home.

Our services include:

• Online doctor consultations with India's largest panel of Ayurvedic and integrative medicine practitioners trained in Vijaya formulations. Consultations are conducted via encrypted video call or text, with digital prescriptions issued to eligible patients.
• Curated product marketplace featuring lab-verified, AYUSH-licensed brands including Cannazo India, Trost, Sanan, Polyherbs, and 20+ other verified Indian cannabis wellness brands.
• Health and wellness collections organised by therapeutic target—sleep, pain, anxiety, immunity—to help you identify the right product format for your specific need.
• Subscription delivery with significant discounts and discreet packaging to all major Indian cities.

Whether you are a first-time Vijaya user researching Cannazo gummies or an experienced consumer looking to optimise your formulation, our medical team is here to guide you through India's evolving cannabis wellness landscape safely and legally.

Key Takeaways: Cannazo India Gummies Summary

Cannazo India's Uplift Gummies represent a thoughtfully formulated, full-spectrum Vijaya extract edible enhanced with Ayurvedic adaptogens including Ashwagandha, lemon extract, pippali, and haritaki. The 1:3 CBD:THC ratio and 315mg cannabinoid payload per gummy make these a meaningfully potent option for consumers targeting sleep, pain, and anxiety wellness goals.

They are legal in India when purchased with a valid AYUSH-licensed prescription from a registered practitioner. The 4–6 hour onset window requires patience and discipline around re-dosing—the single most common mistake with cannabis edibles globally. Full-spectrum THC-containing products are not suitable for everyone, and a medical consultation before first use is both legally required and genuinely advisable.

For Indian consumers navigating the growing landscape of cannabis gummies in India, Cannazo Uplift occupies a clear position: a clinically informed, Ayurveda-enriched, full-spectrum option for users who have completed their medical consultation and want a potent, multi-modal Vijaya product.

Sources & References

1. Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal, 23, 18–041. PMC6326553.
2. Vickery, A. W., & Bhatt, M. (2020). The expanding therapeutic potential of cannabinoids in pain management. Current Psychiatry Reports, 22(11), 62.
3. Devinsky, O., Cross, J. H., Laux, L., et al. (2018). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 376(21), 2011–2020.
4. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
5. Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on ashwagandha: a rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl), 208–213.